PAX3 and neoplasm: A recent publication demonstrated that liposome-protamine-siRNA (LRP) particles targeting PAX3-FOXO1 were efficiently delivered to ARMS cell lines and downregulated PAX3-FOXO1 and its target genes in vitro, leading to delayed tumor growth and inhibition of tumor initiation in ARMS xenograft models (84).